TY - JOUR
T1 - Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak
T2 - A systematic review and meta-analysis
AU - Cho, Wonyoung
AU - Park, Sangil
AU - Kim, Hyeon Jin
AU - Lee, Myeongcheol
AU - Choi, Yong Sung
AU - Yeo, Seung Geun
AU - Lee, Jinseok
AU - Koyanagi, Ai
AU - Jacob, Louis
AU - Smith, Lee
AU - Rahmati, Masoud
AU - Ahmad, Suhana
AU - Fond, Guillaume
AU - Boyer, Laurent
AU - Rhee, Sang Youl
AU - Lee, Seung Won
AU - Shin, Jae Il
AU - Woo, Ho Geol
AU - Yon, Dong Keon
N1 - Publisher Copyright:
© 2024 John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
AB - On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
KW - 2003–2021
KW - 2022
KW - clinical feature
KW - comparison
KW - mpox
KW - outbreak
KW - prevalence
KW - symptom
UR - http://www.scopus.com/inward/record.url?scp=85181524791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181524791&partnerID=8YFLogxK
U2 - 10.1002/rmv.2508
DO - 10.1002/rmv.2508
M3 - Review article
C2 - 38282393
AN - SCOPUS:85181524791
SN - 1052-9276
VL - 34
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
IS - 1
M1 - e2508
ER -